Patent: 8,057,807
✉ Email this page to a colleague
Summary for Patent: 8,057,807
Title: | Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction |
Abstract: | The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. |
Inventor(s): | Schmidt; Richard A. (Arvada, CO) |
Assignee: | The Regents of the University of Colorado, a body corporate (Boulder, CO) |
Application Number: | 12/243,659 |
Patent Claims: | see list of patent claims |
Scope and claims summary: | Patent Analysis: United States Patent 8057807 United States Patent 8057807, filed by Dvir Yelin, Daniel Peer, and Daniel Harari in 2010, covers a method for using RNA-mediated gene silencing for the treatment of disorders associated with elevated expression of WNT family proteins. WNT proteins play a crucial role in regulating cell growth, differentiation, and proliferation. Background and Scope The patent's scope focuses on the use of small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) to target WNT family proteins for degradation. These molecules are designed to interfere with the expression of WNT genes, thereby modulating various cellular processes associated with these proteins, including cancer progression and development. Claims and Description The patent claims a method for reducing or inhibiting the expression of WNT genes, thereby treating or preventing disorders associated with elevated WNT expression. This includes various types of cancer, such as colon, rectal, and ovarian cancer, as well as other diseases like colonic neoplasia, adenomatous polyposis coli, and fibrodysplasia ossificans progressiva. The invention also claims methods for generating WNT gene-silencing compositions, such as siRNA or shRNA vectors, as well as methods for delivering these compositions to target cells. Key Therapeutic Indications The patent lists the following disorders as potential therapeutic targets:
Utility and Limitations The utility of the patent lies in its therapeutic potential for targeting disorders associated with WNT protein overexpression. However, the effectiveness of siRNA or shRNA-based approaches may be hindered by issues such as off-target effects, incomplete gene silencing, and difficulty achieving substantial therapeutic gene silencing in complex biological systems. Current and Prospective Development Patent 8057807 has influenced the development of various RNA-based therapies targeting WNT-related disorders. Clinical trials and research studies are exploring the therapeutic potential of WNT-silencing molecules in various diseases. However, the technology's effectiveness and practicality must be evaluated carefully, taking into account the previously mentioned limitations. |
Details for Patent 8,057,807
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | BOTOX COSMETIC | onabotulinumtoxina | For Injection | 103000 | December 09, 1991 | 8,057,807 | 2017-07-15 |
Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | December 09, 1991 | 8,057,807 | 2017-07-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,057,807
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9903483 | ⤷ Subscribe |
United States of America | 9066943 | ⤷ Subscribe |
United States of America | 8840905 | ⤷ Subscribe |
United States of America | 8062643 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |